Multiple sclerosis: disease-modifying therapies An overview of the available evidence for each disease-modifying therapy for multiple sclerosis, when they are indicated, as well as each stage of patient care.…
Siponimod now recommended for patients with secondary progressive MS Updated draft guidance from the National Institute for Health and Care Excellence has recommended siponimod for the treatment of secondary progressive multiple sclerosis.…
Anticholinergic medications increase risk of mild cognitive impairment, study suggests Anticholinergic medicines more than double the risk of mild cognitive impairment and accelerated memory and language decline in those predisposed to Alzheimer’s disease, a study in Neurology has suggested.…
Considerations for the inpatient management of Parkinson’s disease Recognising and managing certain complications of Parkinson’s disease can help improve care and reduce the risk of admission for people living with the condition.…
Daily naproxen does not stall pre-symptomatic Alzheimer’s in older adults Non-steroidal anti-inflammatory drugs are unlikely to prevent Alzheimer’s disease in people at risk of developing the condition, study authors have concluded.…
Long-term diuretic use may reduce fracture risk in people with Alzheimer’s disease Use of thiazide diuretics for three years or more may reduce the risk of low-energy fracture in people with Alzheimer’s disease, study results have suggested.…
HRT linked to increased Alzheimer’s disease risk in women Hormone replacement therapy is associated with a small but significantly increased risk of Alzheimer’s disease, research published in The BMJ has found…
Motor neurone disease: management of common symptoms There is no cure for motor neurone disease, but symptom control is achievable and can improve quality of life.…
Cannabinoids could help manage spasticity in motor neurone disease An oral spray containing cannabinoids is effective at reducing spasticity symptoms in motor neurone disease, study results have shown.…
Cannabinoids have limited impact on MS symptoms Following a systematic review and meta-analysis researchers have concluded that cannabinoids have limited therapeutic effect on symptoms of multiple sclerosis…
